United Kingdom (UK)
Recombinant monoclonal antibody to Cocaine. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 15A10.
Alternative Name(s) of Target: Benzoylmethylecgonine; coca; coke; crack; ChEBI: 27958
Immunogen: The original antibody was generated by immunizing BALB/c mice with BSA conjugated transition state analogs of cocaine.
Specificity: This antibody hydrolyzes the benzoyl ester of cocaine to form the nonpsychoactive metabolites benzoic acid and ecgonine methylester. Cocaine is a strong stimulant used clinically as a local analgesic and vasoconstrictor and illegally as a recreational drug.
Application Notes: This catalytic antibody is capable of cocaine to its non psychoactive metabolites. The rate of acceleration of the catalytic antibody was reported to be (kcat/kuncat = 2.3 × 10^4). Competitive ELISA was used for the detection of binding of this antibody to the transition-state analogue of cocaine (Yang et al., 1996). In a model of cocaine overdose, this antibody protected rats from cocaine-induced seizures and sudden death in a dose-dependent fashion; a noncatalytic anticocaine antibody did not reduce toxicity. In a model of cocaine addiction, this antibody blocked completely the reinforcing effect of cocaine in rats (PMID: 9707620).
Antibody first published in:
Landry et al. Anti-cocaine catalytic antibodies--a novel approach to the problem of addiction. J Addict Dis. 1997;16(3):1-17. PMID:9243335
Note on publication:
Describes the generation of catalytic antibodies with hydrolytic activity against cocaine.